RT Journal Article
SR Electronic
T1 712 IMPORT-201 (IMP-MEL): a phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist (PORT-2) and pembrolizumab for advanced melanoma and non-small cell lung cancer (NSCLC)
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A807
OP A807
DO 10.1136/jitc-2023-SITC2023.0712
VO 11
IS Suppl 1
A1 Coupe, Nicholas
A1 Pinato, David J
A1 Fairchild, Justin
A1 Poe, Russell
A1 Browne, Carri
A1 Innaimo, Steven
A1 Thompson, David
A1 Gileadi, Uzi
A1 Santo, Carmela De
A1 Kramer, Robert
A1 Walters, Ian
A1 Middleton, Mark R
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A807.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.